Tazobactum%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination penicillin-class antibacterial agent with a beta-lactamase inhibitor. It is active against a broad spectrum of gram-positive and gram-negative aerobic and anaerobic bacteria, including many susceptible to piperacillin alone. ## Primary Indications * Complicated intra-abdominal infections * Complicated skin and skin-structure infections * Community-acquired pneumonia * Nosocomial pneumonia * Febrile neutropenia (empiric treatment) * Bacterial meningitis (in certain situations) * Other serious bacterial infections when suspected or confirmed to be caused by piperacillin-susceptible, beta-lactamase-producing bacteria. ## Adult Dosing The typical dose is 3.375 grams (3g piperacillin/0.375g tazobactam) or 4.5 grams (4g piperacillin/0.5g tazobactam) intravenously every 6 to 8 hours. Duration of therapy is dependent on the severity and type of infection, typically ranging from 7 to 14 days. For febrile neutropenia, doses are often given every 8 hours. Specific dosing for severe infections or empiric treatment of febrile neutropenia may be guided by local institutional protocols. ## Pediatric Dosing Dosing is based on the piperacillin component. * **Patients 2 months to 12 years:** * For complicated intra-abdominal infections: 100 mg piperacillin/12.5 mg tazobactam per kg body weight given every 8 hours. * For hospital-acquired pneumonia: 100 mg piperacillin/12.5 mg tazobactam per kg body weight given every 8 hours. * For febrile neutropenia: 100 mg piperacillin/12.5 mg tazobactam per kg body weight given every 8 hours. * Maximum dose: 4.5 grams per dose. * **Patients older than 12 years:** Dosing is the same as for adults. * **Neonates and infants younger than 2 months:** Safety and efficacy have not been established, and use is generally not recommended. ## Dose Adjustments * **Renal Impairment (CrCl < 40 mL/min):** * For 3.375 g every 6 hours: Administer 2.25 g every 6 hours. * For 4.5 g every 6 hours: Administer 3.375 g every 6 hours. * For 3.375 g every 8 hours: Administer 2.25 g every 8 hours. * For 4.5 g every 8 hours: Administer 3.375 g every 8 hours. * For patients on intermittent hemodialysis, administer the usual dose (adjusted for CrCl) every 8 hours and an additional dose after each dialysis session. * **Hepatic Impairment:** No dose adjustment is generally needed. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, other beta-lactam antibiotics, or any component of the formulation. * History of immediate or severe allergic reaction to a beta-lactam antibacterial. ## Adverse Effects Common adverse effects include diarrhea, nausea, vomiting, rash, headache, insomnia, constipation, and elevated liver enzymes. Less common but serious adverse effects include C. difficile-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures, neutropenia, thrombocytopenia, and interstitial nephritis. ## Key Drug Interactions * **Aminoglycosides:** Concurrent administration may lead to inactivation of piperacillin; however, in severe infections, combination therapy may be beneficial. Separate administration if possible. * **Probenecid:** May increase and prolong serum concentrations of piperacillin and tazobactam. * **Neuromuscular blocking agents:** Piperacillin may prolong the action of vecuronium. Monitor neuromuscular function. * **Warfarin:** May decrease the anticoagulant effect of warfarin. Monitor INR closely. * **Methotrexate:** Piperacillin may decrease methotrexate clearance. Monitor methotrexate levels. ## Monitoring * Renal function (baseline and during therapy, especially in elderly patients or those with pre-existing renal disease). * Liver function tests. * Complete blood count (CBC) with differential, especially with prolonged therapy. * Signs and symptoms of infection, including fever, white blood cell count, and inflammatory markers. * Signs and symptoms of hypersensitivity reactions. * Monitor for diarrhea and C. difficile infection. ## Clinical Pearls * Tazobactam protects piperacillin from degradation by many beta-lactamases, expanding its spectrum of activity. * Dosing frequency (every 6 or 8 hours) is often dictated by the indication and severity of illness, with more frequent dosing sometimes used for empiric treatment of febrile neutropenia or severe infections. Always consult local protocols. * Adequate hydration is important during administration to prevent crystalluria. * Sodium content should be considered in patients requiring sodium restriction. *** **Disclaimer:** This information is intended for clinical use and does not replace professional medical judgment. Always consult the most current prescribing information and relevant clinical guidelines for definitive guidance.